Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Alliance for Clinical Trials in Oncology
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04137107
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Intervention
Duloxetine, Duloxetine Hydrochloride, Oxaliplatin, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Condition
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Investigators
Ellen M. Lavoie Smith, PhD, Dennis Hsu, Site Public Contact, Richard L. Deming, Elie G. Dib